Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo

References

• CaoSMSimonsMJQianCNThe prevalence and prevention of nasopharyngeal carcinoma in ChinaChin J Cancer201130211411921272443
   PubMedGoogle Scholar
• WeiKRZhengRSZhangSWLiangZHOuZXChenWQNasopharyngeal carcinoma incidence and mortality in China in 2010Chin J Cancer201433838138725096544
   PubMedGoogle Scholar
• ZhangLFLiYHXieSHIncidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysisChin J Cancer201534835035726058679
   PubMedGoogle Scholar
• AuEAngPTA phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinomaAnn Oncol19945187898172799
   PubMed Web of Science ®Google Scholar
• WangTLTanYOCisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinomaAnn Acad Med Singapore19912056016031781642
   PubMedGoogle Scholar
• MaBBHuiEPWongSCMulticenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma – correlation with excision repair cross-complementing-1 polymorphismsAnn Oncol200920111854185919549713
   PubMed Web of Science ®Google Scholar
• NganRKYiuHHLauWHCombination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II studyAnn Oncol20021381252125812181249
   PubMed Web of Science ®Google Scholar
• ZhangLZhangYHuangPYXuFPengPJGuanZZPhase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapyCancer Chemother Pharmacol2008611333817909810
   PubMed Web of Science ®Google Scholar
• Guang-WuHSunagawaMJie-EnLThe relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinomaLaryngoscope2000110122066206911129022
   PubMed Web of Science ®Google Scholar
• HuiEPChanATPezzellaFCoexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survivalClin Cancer Res2002882595260412171890
   PubMed Web of Science ®Google Scholar
• KrishnaSMJamesSBalaramPExpression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV statusVirus Res20061151859016139912
   PubMed Web of Science ®Google Scholar
• LiYHHuCFShaoQElevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinomaJ Transl Med20086118171482
   PubMed Web of Science ®Google Scholar
• ShaDHeYJExpression and clinical significance of VEGF and its receptors Flt-1 and KDR in nasopharyngeal carcinomaAi Zheng2006252229234 Chinese16480593
   PubMedGoogle Scholar
• RiniBISorafenibExpert Opin Pharmacother20067445346116503817
   PubMed Web of Science ®Google Scholar
• RiniBISunitinibExpert Opin Pharmacother20078142359236917927489
   PubMed Web of Science ®Google Scholar
• CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell20058429930916226705
   PubMed Web of Science ®Google Scholar
• FernandoNTKochMRothrockCTumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factorsClin Cancer Res20081451529153918316578
   PubMed Web of Science ®Google Scholar
• HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
   PubMed Web of Science ®Google Scholar
• KudoKAraoTTanakaKAntitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivoClin Cancer Res20111761373138121131553
   PubMed Web of Science ®Google Scholar
• PoindessousVOuaretDEl OuadraniKEGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodiesClin Cancer Res201117206522653021880790
   PubMed Web of Science ®Google Scholar
• ReckMKaiserRMellemgaardALUME-Lung 1 Study GroupDocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• ZhaoYYXueCJiangWPredictive value of intratumoral micro-vascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumabJ Thorac Oncol201271717522011670
   PubMed Web of Science ®Google Scholar
• WeidnerNIntratumor microvessel density as a prognostic factor in cancerAm J Pathol199514719197541613
   PubMed Web of Science ®Google Scholar
• Chinese University of Hong KongNasopharyngeal Carcinoma (NPC) Axitinib Available from: https://www.clinicaltrials.gov/ct2/show/NCT01249547. NLM identifier: NCT01249547Accessed February 12, 2016
   Google Scholar
• ElserCSiuLLWinquistEPhase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinomaJ Clin Oncol200725243766377317704426
   PubMed Web of Science ®Google Scholar
• HuiEPMaBBKingADHemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiationAnn Oncol20112261280128721317222
   PubMed Web of Science ®Google Scholar
• LeeNYZhangQPfisterDGAddition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trialLancet Oncol201213217218022178121
   PubMed Web of Science ®Google Scholar
• LimWTNgQSIvyPA phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinomaClin Cancer Res201117165481548921712450
   PubMed Web of Science ®Google Scholar
• XueCHuangYHuangPYPhase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinomaAnn Oncol20132441055106123172635
   PubMed Web of Science ®Google Scholar
• ZipsDEichelerWGeyerPEnhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibitionCancer Res200565125374537915958586
   PubMed Web of Science ®Google Scholar
• BrownAPCitrinDECamphausenKAClinical biomarkers of angiogenesis inhibitionCancer Metastasis Rev200827341543418414993
   PubMed Web of Science ®Google Scholar
• SessaCGuibalADel ConteGRüeggCBiomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?Nat Clin Pract Oncol20085737839118560389
   PubMedGoogle Scholar